[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628226":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":17,"centralContacts":24,"locations":30,"responsibleParty":75,"collaborators":79,"id":87,"slug":17,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":17,"enrollmentInfo":96,"targetDuration":17,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":49,"whyStopped":17,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Triple antihypertensive medication group","ACTIVE_COMPARATOR","Triple antihypertensive medication Amlodipine 5mg\u002F Valsartan 160mg\u002F Hydrochlorothiazide 12.5mg, either as triple pill or three individual component drugs, on Day 3 after ICH. Dosage will be increased to Amlodipine 10\u002F Valsartan 160\u002F Hydrochlorothiazide 25, if SBP remained \\>130 mmHg on Day 7, or early if deemed necessary. Further anti-hypertensive medication titration will be made by the research team in consultation with the treating medical team as appropriate during the study period.",[13],"Drug: Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide",{"label":15,"type":16,"description":17,"interventionNames":17},"Control group","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":17},"DRUG","Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide","Three antihypertensive medication will be prescribed, either as a fixed-dose, single-pill combination (triple pill) containing three antihypertensive agents with complementary mechanisms of action: amlodipine 5mg, valsartan 160mg, and hydrochlorothiazide 12.5mg, or as three individual drugs. Use of the triple pill will depend on the patient's ability to swallow an intact tablet (it cannot be crushed) and on local availability. This specific combination targets multiple pathways involved in blood pressure regulation: calcium channel blockade reduces peripheral vascular resistance, angiotensin II receptor blockade inhibits the renin-angiotensin-aldosterone system, and thiazide diuresis reduces plasma volume and further lowers vascular resistance",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":17,"email":29},"Kay Cheong TEO","CONTACT","+852 2255 5318","kcteo@hku.hk",[31,47,55,65],{"facility":32,"status":33,"city":34,"state":34,"zip":17,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Princess Margaret Hospital","NOT_YET_RECRUITING","Hong Kong","HK",{"type":37,"coordinates":38},"Point",[39,40],114.17469,22.27832,{"lat":40,"lon":39},[43],{"name":44,"role":27,"phone":45,"phoneExt":17,"email":46},"Jerome Hiu Fung WU","+852 6461 1080","hf.wu@ha.org.hk",{"facility":48,"status":49,"city":34,"state":34,"zip":17,"country":34,"countryCode":35,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"Queen Mary Hospital","RECRUITING",{"type":37,"coordinates":51},[39,40],{"lat":40,"lon":39},[54],{"name":26,"role":27,"phone":28,"phoneExt":17,"email":29},{"facility":56,"status":33,"city":34,"state":34,"zip":17,"country":34,"countryCode":35,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Ruttonjee Hospital",{"type":37,"coordinates":58},[39,40],{"lat":40,"lon":39},[61],{"name":62,"role":27,"phone":63,"phoneExt":17,"email":64},"Chung Hon KWAN","+852 5928 3354","kch076@ha.org.hk",{"facility":66,"status":33,"city":34,"state":34,"zip":17,"country":34,"countryCode":35,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Yan Chai Hospital",{"type":37,"coordinates":68},[39,40],{"lat":40,"lon":39},[71],{"name":72,"role":27,"phone":73,"phoneExt":17,"email":74},"Joshua Wai Ming FOK","+852 6626 4603","fwm471@ha.org.hk",{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Teo Kay-Cheong","Clinical Assistant Professor",[80,83,86],{"name":81,"class":82},"Princess Margaret Hospital, Hong Kong","OTHER_GOV",{"name":84,"class":85},"Ruttonjee Hospital, Hong Kong","UNKNOWN",{"name":66,"class":6},"100628226",false,"NCT07458880","Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control","TRIple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure ConTrol With the TRICH Score","TRIACT","Inclusion Criteria:\n\n1. Spontaneous ICH\n2. Age ≥18 years\n3. Premorbid modified Rankin Scale of ≤3\n4. TRICH score ≥3\n5. Within 1 week of ICH\n\nExclusion Criteria:\n\n1. Glasgow coma score \\\u003C9\n2. Expected life expectancy of six months\n3. Admission SBP \\\u003C160mmHg\n4. Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula \\\u003C30 ml\u002Fmin\u002F1.73m2\n5. Inability to perform home BP monitoring\n6. Inability to participate in follow-up activity\n7. Hypersensitivity to study drug\n8. Known contraindication to amlodipine\n9. Known contraindication to valsartan\n10. Known contraindication to hydrochlorothiazide\n11. Any conditions that investigator deems that patient is not suitable of any component of the triple pill or antihypertensive medications in general","ALL","18 Years",{"count":97,"type":98},140,"ESTIMATED","INTERVENTIONAL",[101],"NA","Intracerebral hemorrhage (ICH) is the second most common form of stroke, with an incidence of around 3000 cases per year in Hong Kong. Although it only accounts for around 20-30% of all strokes, ICH is the most severe form of stroke, contributing to 50% of all stroke mortality and the greatest disability burden in stroke. For those who survive their ICH, they are at high risk of ICH recurrence, stroke, cardiovascular event and death. Hence, reducing these risks after ICH is a top priority to lessen the disease's healthcare and social burden.\n\nHypertension is the main driver for ICH, and achieving blood pressure (BP) control significantly reduces the risk of recurrent ICH, stroke and cardiovascular events. However, only 50% of ICH survivors achieved BP control after ICH. This is because ICH patients represent a unique hypertensive population with more difficult-to-control BPs, with many requiring ≥3 antihypertensive medications. Many reasons contribute to uncontrolled hypertension, but inadequate prescription of medication is the most actionable cause. The notion of an upfront prescription of a triple antihypertensive regimen (triple pill) soon after ICH could consequent better BP control, but there are concerns of excessive lowering of BP, particularly in older patients, which has been associated with increased mortality. This approach may also not be suitable for ICH patients with cerebral amyloid angiopathy where the elevated admission BP may be due to acute hypertensive response rather than underlying hypertension. Additionally, the general use of upfront triple pill in all ICH would have healthcare implications, as triple pills are more expensive compared to conventional antihypertensive medications.\n\nTo facilitate individualized treatment, a predictive score, the TRICH score, was recently developed and validated to identify patients who require triple pills after ICH. Therefore, the current TRIACT study aims to test the clinical application and benefit of the TRICH score for the upfront prescription of triple antihypertensive medication after ICH to enable prompt achievement of BP control.",[104],"Intracerebral Hemorrhage",[104,106,107],"Triple antihypertensive medication","Blood pressure control","2026-03-04",{"date":110,"type":111},"2026-03-09","ACTUAL",{"date":113,"type":111},"2026-03-01",{"date":115,"type":98},"2030-06-30",{"name":5,"class":6},4]